Alendronate Sodium
Product Images NDC 68071-4120

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68071-4120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 4120 01 A161)

Pdp (68071 4120 01 A161)
This is a description of a medication called Alendronate Sodium 70mg, which comes in a pack of 12 tablets. The medication is being produced by NuCare Pharmaceuticals, Inc. The lot number for this batch is 000000, and the expiration date is 00-00. The National Drug Code (NDC) for this medication is 68071-4120-1. The pack also includes a warning to keep it out of the reach of children, and a note to store it at a controlled temperature of 59-36 °F.*
FDA Label Image

Structural Formula For Alendronate Sodium (Alendronate Sodium Tablets 3)

FDA Label Image

Cumulative Incidence Of Hip Fractures In The Three-year Study Of Fit (patients With Radiographic Vertebral Fracture At Baseline) (Alendronate Sodium Tablets 4)

FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Increase In Bmd Alendronate Sodium 10 mg/day At Three Years (Alendronate Sodium Tablets 5)

FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Time Course Of Effect Of Alendronate Sodium 10 mg/day Versus Placebo: Lumbar Spine Bmd Percent Change From Baseline (Alendronate Sodium Tablets 6)

FDA Label Image

Osteoporosis Prevention Studies In Postmenopausal Women (Alendronate Sodium Tablets 7)

FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year)

FDA Label Image

Studies In Paget’s Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate Sodium 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Sodium Tablets 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.